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Abstract: S-CKD602 is a PEGylated liposomal formulation of CKD-602, a potent 
topoisomerase I inhibitor. The objective of this study was to characterize the bidirectional 
pharmacokinetic–pharmacodynamic (PK–PD) interaction between S-CKD602 and monocytes. 
Plasma concentrations of encapsulated CKD-602 and monocytes counts from 45 patients with 
solid tumors were collected following intravenous administration of S-CKD602 in the phase 
I study. The PK–PD models were developed and fit simultaneously to the PK–PD data, using 
NONMEM®. The monocytopenia after administration of S-CKD602 was described by direct 
toxicity to monocytes in a mechanism-based model, and by direct toxicity to progenitor cells in 
bone marrow in a myelosuppression-based model. The nonlinear PK disposition of S-CKD602 
was described by linear degradation and irreversible binding to monocytes in the mechanism-
based model, and Michaelis–Menten kinetics in the myelosuppression-based model. The 
mechanism-based PK–PD model characterized the nonlinear PK disposition, and the bidirectional 
PK–PD interaction between S-CKD602 and monocytes.
Keywords: population pharmacokinetics, pharmacodynamics, PEGylated liposome, nonlinear 
kinetics
Introduction
S-CKD602 is a sterically stabilized PEGylated liposomal formulation of CKD-602. 
CKD-602 is a novel camptothecin analog which inhibits topoisomerase I.1–3 
Nonliposomal CKD-602 administered intravenously (IV) at 0.5 mg/m2/day for five 
consecutive days every 3 weeks has been approved in Korea for the treatment of small 
cell lung cancer, and relapsed ovarian cancer.4–7 S-CKD602 STEALTH® liposomes are 
composed of the lipids distearoylphosphatidylcholine and distearoylphosphatidyletha-
nolamine, covalently bound to N-(carbonylmethoxypolyethylene glycol 2000)-1,2-dis-
tearoyl-sn-glycero-3 phosphoethanolamine sodium salt (DSPE-MPEG-2000).1,8 The 
average particle size of the S-CKD602 liposomes is ∼100 nm. In this formulation, CKD-
602 lactone is encapsulated in the aqueous core of the liposome with an encapsulation 
efficiency of .85%.1,8 Encapsulation of the CKD-602 in the acidic core of a PEGy-
lated liposome protects the biologically active lactone form of the drug from being 
converted to the inactive hydroxyacid form in the blood. The liposomal encapsulation 
also allows release of the active-lactone form into the tumor over a prolonged period 
of time, which is ideal for a cell-cycle-specific drug.3,9–13
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The pharmacokinetic (PK) disposition of carrier-
mediated agents, such as nanoparticles, nanosomes, and 
conjugated agents, is dependent upon the carrier until 
the drug is released from the carrier. Unlike traditional 
anticancer agents, which are cleared by the liver and kidneys, 
the clearance of non-PEGylated and PEGylated liposomes 
occurs via the mononuclear phagocytic system (MPS), 
which include monocytes, macrophages, and dendritic cells 
located primarily in blood, liver, and spleen.14 PEGylated 
liposomes are cleared much slower via MPS compared with 
non-PEGylated liposomes.15,16 Uptake of the liposomes, or 
nanoparticles, by the MPS usually results in sequestering 
of the encapsulated drug in the MPS. The sequestered drug 
in the MPS may cause acute and/or long-term cytotoxicity 
to the MPS. This toxicity to the MPS, in turn decreases 
clearance of the PEGylated liposomal anticancer agents, 
and alters the pharmacodynamics (PD) of the agents. Thus, 
there is a bidirectional interaction between PEGylated 
liposomal anticancer agents and MPS. Since a major 
portion of the liposomal-encapsulated drug molecules are 
confined primarily to the blood compartment due to their 
relative large size, this bidirectional interaction between 
PEGylated liposomal anticancer agents and monocytes in 
blood is very important in determining the PK and PD of 
PEGylated liposomal anticancer agents, and potentially other 
nanoparticle and conjugated agents.17
As monocytes of the MPS play an important role in the PK 
disposition of liposomes, monocytopenia after administration 
of PEGylated liposomal anticancer agents was selected as 
a PD measure of these agents.2,16 Monocytopenia is also 
commonly observed after small-molecule chemotherapy, as a 
result of myelosuppression.18,19 However, the monocytopenia 
is greater and occurs earlier after administration of liposomal 
agents compared with nonliposomal agents.2,16 The results of 
our prior study suggest that monocytes are more sensitive 
to S-CKD602 as compared with neutrophils, and that this 
increased sensitivity is related to the liposomal formulation 
and not the encapsulated CKD-602.16 Therefore, the 
monocytopenia following administration of PEGylated 
liposomal agents may have a different mechanism from 
monocytopenia following treatment with conventional 
small-molecule chemotherapeutic drugs. Incorporation 
of the bidirectional interaction between PEGylated 
liposomal formulation and monocytes is important to the 
characterization of this novel PK and PD of these agents.
Although a few physiologically-based PD models of 
chemotherapy-induced anemia, neutropenia, and thrombo-
cytopenia have been developed, PD models of monocytopenia, 
especially as related to nanoparticle PK and PD, have not 
been reported.20–24 As monocytes are derived from the 
same granulocyte-macrophage progenitor cells as other 
leukocytes, PD models of leukocytopenia may be applicable 
to monocytopenia. A semiphysiological model proposed by 
Friberg et al20,21 for chemotherapy-related myelosuppression 
was chosen as a standard model to describe monocytopenia 
after S-CKD602. In this model, the cell maturation associated 
with myelopoiesis is described by multiple transit compart-
ments with the same rate constant between each compart-
ment, to account for the time delay for onset of response.20,21 
In addition, a feedback loop was included to account for the 
rebound of leukocytes typically observed in myelosuppres-
sion profiles. This model has been widely applied to various 
anticancer agents to describe neutropenia, leukocytopenia, 
and thrombocytopenia because it involves minimum number 
of parameters.21,25–29
The clinical results of the phase I and PK study of 
S-CKD602 have been previously published.30 The PK study 
of S-CKD602 using the conventional compartment model 
has also been published, and the dose-dependent clearance 
of S-CKD602 was modeled using Michaelis–Menten 
kinetics.31 This is the first study to evaluate the bidirectional 
interaction between a nanoparticle agent and the monocytes 
of the MPS in patients using PK–PD modeling. These 
findings and approach can be applied to the more than 300 
other nanoparticle formulations of anticancer agents that are 
currently in development. Thus, this is a very novel study 
with a far-reaching impact.
The conventional theory is that the monocytopenia 
of small-molecule chemotherapy is due to cytotoxicity 
to the progenitor cells in the bone marrow. However, it 
is unclear whether the monocytopenia associated with 
liposomal agents is due to direct cytotoxicity to monocytes 
in the blood, or cytotoxicity to progenitor cells in bone 
marrow. We believe the bidirectional interaction between 
PEGylated liposomal anticancer drugs and monocytes in 
blood is important to characterize the monocytopenia after 
administration of these agents and how monocytopenia 
affects PK of these agents. We developed mechanism-based 
PK–PD models based on direct and on indirect cytotoxicity 
of S-CKD602 to monocytes, and compared the model fit 
of these two models. The objectives of this study were to 
develop a mechanism-based population PK–PD model to 
investigate the nature of nonlinear PK of S-CKD602, and to 
increase our understanding of the bidirectional interaction 
between PEGylated liposomal anticancer agents and 
monocytes in the blood of cancer patients.
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Methods
Study design
The PK data were obtained from a Phase I study of 
S-CKD602 in patients with advanced solid tumors.30,31 
The study design and clinical results have been reported 
elsewhere.30,31 Forty-five patients (21 males) received 
S-CKD602 at 0.1 to 2.5 mg/m2 IV × 1 over approximately 
1 hour, every 3 weeks. No premedications were administered 
prior to S-CKD602. Written informed consent, which 
had been approved by the Institutional Review board 
of the University of Pittsburgh Medical Center, was 
obtained from all patients prior to study entry. Patients 
$ 18 years of age with histologically or cytologically 
confirmed malignancies for which no effective therapy 
was available, and with an Eastern Cooperative Oncology 
Group performance status of 0–2, were eligible for this 
study. Pertinent eligibility criteria included adequate bone 
marrow, as well as hepatic and renal function evidenced by 
the following laboratory parameters: (i) absolute neutrophil 
count $ 1,500/µL, (ii) platelet count $ 100,000/µL, 
(iii) total bilirubin # 1.5 × upper limit of the institutional 
normal range, (iv) aspartate aminotransferase # 1.5 × upper 
limit of the institutional normal range if liver metastases were 
not present and #4 × ULN if liver metastases were present, 
and (v) the absence of microscopic hematuria published.30,31 
The mean age of the patients was 60.6 (range 33–79) 
years. In this study, serial plasma samples were obtained 
prior to drug administration; at the end of the infusion (at 
around 1 hour); and at 3, 5, 7, 24, 48, 72, 96, 168 (day 8), 
and 336 hours (day 15) after the start of the infusion. Total 
(lactone + hydroxyl acid) concentrations of encapsulated 
and released CKD-602 in plasma were determined by liquid 
chromatography-tandem mass spectrometry.1 The lower limit 
of quantitation of the total form of encapsulated and released 
CKD-602 were 2 ng/mL and 0.05 ng/mL, respectively. 
Samples of peripheral blood were collected before dosing 
on days 7, 14, 21, and 28 and used to measure monocyte 
counts. Monocyte count in blood was determined by standard 
clinical hematology methods.32
Population PK–PD analysis
Model development
The bidirectional interaction between PEGylated liposomal 
anticancer agents and monocytes plays a key role in the 
elimination of PEGylated liposomal anticancer agents and 
monocytopenia observed in our prior studies.16 A mechanism-
based model based on receptor binding kinetics was devel-
oped to describe the bidirectional interaction between the 
concentration versus time profile of encapsulated CKD-602, 
and the time course of monocytes. A myelosuppression-
based model, in absence of the bidirectional interaction, 
was also developed to compare with the mechanism-based 
model. For each kind of model, a variety of model structures 
were tested. The best models were selected on the basis of 
Akaike’s information criterion, precision of estimates, and 
goodness-of-fit plots.33
Model I: myelosuppression-based model
The PK–PD model of encapsulated CKD-602 and 
monocytes was built sequentially. One compartment model 
with Michaelis–Menten kinetics best described the PK 
data of encapsulated CKD-602 in our previous analysis. 
The individual PK parameters of encapsulated CKD-602 
determined from the best PK model of encapsulated CKD-
602 were used in the PD model of monocytes. In the PK 
modeling part, PK parameters were estimated for each 
individual. For the PD modeling of monocytopenia, all of 
the individual values of the PK parameters were fixed for 
each patient, and the predicted individual encapsulated 
CKD-602 concentration–time profiles were used as input 
functions into this PK–PD model. The PD parameters 
were estimated simultaneously in the PD modeling part. 
This sequential modeling approach was selected over 
a simultaneous PK–PD estimation, to expedite the PD 
modeling by using the existing individual estimates of 
PK parameters.
A chemotherapy-induced myelosuppression model 
developed by Friberg et al21 was used to describe the 
monocytopenia after administration of S-CKD602 
(Figure 1A). The model consists of a proliferating 
compartment (Prol) that represents progenitor cells, three 
transit compartments of maturing cells (Transit), and a 
compartment of circulating monocytes. A negative feedback 
mechanism (MONO
0
/MONO)γ from circulating cells on 
proliferating cells is included to describe the rebound of cells 
including an overshoot compared with the baseline value 
(MONO
0
). The drug concentration in plasma of the central 
compartment (C
p
) is assumed to reduce the proliferation rate 
by the function E
Drug
, which was modeled to be a maximum-
attainable effect (E
max
) model. The differential equations 
were written as
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where dA
Encap
/dt is the elimination rate, V
max
 is the maximum 
elimination rate or maximum velocity, K
m
 is the concentration 
at which half-maximum elimination rate is achieved, V
Encap
 is 
the volume of distribution, A
Encap
 is encapsulated CKD-602 
amount in plasma, C
Encap
 is the plasma concentration of encap-
sulated CKD-602, k
0
 is the infusion rate and k
0
 is 0 after stop 
of infusion, k
tr
 is the transit rate constant, E
max
 is the maximum 
k0
kprol = ktr 
VEncap
V
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I
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Transit 1 Transit 2 Transit 3 Circulating
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Figure 1 The myelosuppression-based PK–PD model (A) and the mechanism-based 
PK–PD model (B) for encapsulated CKD-602 and monocytes. 
Abbreviations: PK–PD, pharmacokinetic-pharmacodynamic; VEncap, volume of 
distribution; k0, infusion rate; Km, concentration at which half-maximum elimination 
rate is achieved; Vmax, maximum elimination rate; Imax, maximum capacity of inhibition; 
IC50, concentration at which half-maximum inhibition is achieved; kprol, proliferation 
rate constant; ktr, transit rate constant; kmono, removal rate constant of monocyte; 
Mono, monocyte count; Mono0, baseline monocyte count; γ, feedback constant; 
kdeg, degradation rate constant; kin, monocyte production rate constant; kout, monocyte 
removal rate constant; IV, intravenous.
attainable effect, EC
50
 is the concentration producing 50% of 
E
max
, Mono
0
 is the baseline monocyte count, γ is the feedback 
constant, k
prol
 is the proliferation rate constant, k
mono
 is the 
removal rate constant of monocyte, Mono is the monocyte 
count. The drug concentration in the central compartment 
is assumed to reduce the proliferation rate by the function 
E
Drug
. At steady state, dProl/dt = 0, and therefore k
prol
 = k
tr
. 
To minimize the number of parameters to be estimated, it 
was assumed in the modeling that k
mono
 = k
tr
.
Model II: mechanism-based PK–PD model
A mechanism based PK–PD model that incorporates the 
interaction between PEGylated liposomal anticancer agents 
and monocytes was developed for S-CKD602 (Figure 1B). 
Concentration versus time data of encapsulated CKD-
602 in plasma and monocyte count in blood were f it 
simultaneously by this model. Drug is dosed IV into the 
systemic circulation (blood compartment) at a zero-order 
rate (k
0
). The distribution of PEGylated liposome is 
described by a one-compartment model and the PEGylated 
liposome is eliminated by interacting with monocyte to 
form liposome-monocyte complex (k
a
), which represents 
the phagocytosis of S-CKD602 by the monocyte. PEGylated 
liposome is also degraded at a first-order rate (k
deg
). This 
represents the elimination of the liposome through routes 
other than uptake by monocytes. The parameters describing 
the production and loss of monocytes are k
in
 and k
out
. The 
production rate of monocytes k
in
 is equal to k
out
 multiplied 
by baseline monocyte value. The differential equations 
were written as:
 
dA
dt
k k A Mono k A
Encap
a Encap Encap= − − =0 ⋅  ⋅ ⋅deg , A (0) 0Encap
 
dMono
dt
Mono k k Mono k A
Mono SFactor
out out a Encap= - -0 ⋅ ⋅ ⋅ 
⋅ / , Mono (0) = Mono0
 
C
A
VEncap
Encap
Encap
=  (2)
where k
a
 is the association rate constant, k
deg
 is the degra-
dation rate constant of S-CKD602, and k
out
 is the removal 
rate constant of monocyte. Since the unit of encapsulated 
CKD-602 is µg/L and the unit of monocyte count is 109/L, 
the drug amount-monocyte count conversion factor (SFactor) 
is a parameter used to bridge the unit gap.
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Data analysis
Plasma concentrations of encapsulated CKD-602 and 
monocyte counts were obtained from 45 patients. A total of 
292 plasma concentrations of encapsulated CKD-602 and 
123 monocyte counts were used to develop the population 
PK–PD model. Encapsulated CKD-602 concentration versus 
time profile and monocyte count versus time data were ana-
lyzed using the nonlinear mixed-effects modeling approach, 
as implemented in NONMEM® (version 6; University of 
California, San Francisco, CA), for the mechanistic- and 
myelosuppression-based models. The first-order condi-
tional estimation method was used in analyses. S-PLUS 8.0 
(Version 8.0, Insightful Corporation, Seattle, WA) was used 
for graphical diagnostics.
Mean population PK–PD variables, interindividual vari-
ability (IIV), and residual error were assessed in the model 
development.34,35 IIV for each PK–PD variable was modeled 
with an exponential function. Residual error models of the 
additive, proportional, exponential, and combination methods 
were evaluated for the best structural PK–PD model. Indi-
vidual PK–PD variables were obtained by posterior Bayesian 
estimation.34,35
Results
Model I: myelosuppression-based model
Goodness-of-fit plots from the myelosuppression-based PK–PD 
model in all patients are depicted in Figure 2A. The model 
adequately describes the PK profile of encapsulated CKD-602. 
The observed PK data correlated well with the population- 
predicted (R2 = 0.80) and individual-predicted (R2 = 0.98) 
data by this model. Although the PD data of monocytes were 
variable, the observed and model-predicted data agreed rela-
tively well. The observed PD data better correlated with the 
individual-predicted PD data (R2 = 0.83) than with population-
predicted PD data (R2 = 0.43). Representative individual PK 
profiles of encapsulated CKD-602 and time course of monocy-
topenia in patients are shown in Figure 2B. The observed data 
of encapsulated CKD-602 and monocytes were well described 
by the myelosuppression-based model.
The encapsulated CKD-602 and monocytes were 
modeled sequentially for all patients. The distribution of 
residual variability was best described by a proportional 
error model. The PK and PD parameter estimates obtained 
from the final model are provided in Table 1. In the final 
model, the mean and IIV(coefficient of variation %) values 
for V
encap
 were 3.46 L and 78.6%, respectively. The esti-
mated V
encap
 was very close to plasma volume in humans. 
The mean Michaelis–Menten constant was estimated to be 
877 µg/L. The maximum velocity of encapsulated CKD-602 
was estimated to be 95.5 (IIV 234%) µg/h. The mean transit 
compartment rate constant was estimated to be 0.0774 h-1. 
The mean maximum inhibition effect was estimated to 
be 0.64. The inhibition constant of S-CKD602 was estimated 
to be 355 (IIV 146%) µg/L. The baseline monocyte value 
was estimated to be 0.605 (IIV 35.5%) × 109/L. The mean 
feedback constant was estimated to be 0.0955.
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Figure 2 Goodness-of-fit plots for the myelosuppression-based model (A); and representative individual plots of observed (○) and individual-predicted (—) values of 
encapsulated CKD-602 and monocytes from the myelosuppression-based model (B). 
Note: The solid lines in Figure 2A are lines of identity.
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Model II: mechanism-based PK–PD model
Goodness-of-fit plots from the mechanism-based PK–PD 
model in all patients are depicted in Figure 3A. Similar to the 
myelosuppression-based model, the population-predicted and 
individual-predicted encapsulated CKD-602 concentrations 
were highly correlated with the observed values, and the 
observed and model-predicted data agreed relatively well. 
Representative individual PK profiles of encapsulated CKD-
602 and time course of monocytopenia in patients are shown 
in Figure 3B. The observed data of encapsulated CKD-602 
Table 1 Population PK–PD parameters obtained from the myelosuppression-based model for encapsulated CKD-602 and monocytes
Parameter Definition Population mean  
RSEa (%)
IIVb, CV%c 
RSEa (%)
VEncap (L) Volume of distribution for encapsulated CKD-602 3.46 (7.8) 70.9 (43)
Vmax (µg/h) Maximum velocity of encapsulated CKD-602 95.5 (31) 234 (34)
km (µg/L) Michaelis–Menten constant 877 (21) NE (NA)
d
Mono0 (10
9/L) Baseline monocyte count 0.605 (14) 35.5 (43)
ktr (1/h) Transit rate constant 0.0774 (7.7) NE (NA)
d
Emax Maximum inhibition 0.64 (31) NE (NA)
d
EC50 (µg/L) Inhibition constant 355 (60) 146 (80)
γ Feedback constant 0.0955 (12) NE (NA)d
Residual variability
Proportional error (variability as %) 
 Encapsulated CKD-602 
 Monocytes
 
13.3% (52) 
37.3% (36)
 
NAd 
NAd
Additive error 
 Encapsulated CKD-602 (µg/L) 
 Monocytes (109/L)
 
8.66 (54) 
NE (NA)
 
NAd 
NAd
Notes: aRelative standard error for estimate; binterindividual variability; ccoefficient of variation; dNE, not estimated; NA, not applicable.
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Figure 3 Goodness-of-fit plots for the mechanism-based model (A); and representative individual plots of observed (○) and individual-predicted (—) values of encapsulated 
CKD-602 and monocytes from the mechanism-based model (B). 
Note: The solid lines in Figure 3A are lines of identity.
concentration and monocytes were well described by the 
mechanism-based model.
The encapsulated CKD-602 and monocytes were mod-
eled simultaneously for all patients. The distribution of 
residual variability was best described by a proportional 
plus additive error model. The PK–PD parameter estimates 
obtained from the final model are provided in Table 2. The 
V
encap
 was estimated to be 4.1 L (IIV 58.9%). The estimated 
V
encap
 is close to the plasma volume in humans. The mean 
association rate constant was estimated to be 1.9 L ⋅ h-1. 
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The k
deg
 was estimated to be 0.0178 (IIV 50.6%) h-1. The 
baseline monocyte value was estimated to be 0.671 (IIV 
29.9%) × 109/L. The removal rate constant of monocytes 
was estimated to be 0.00677 (IIV 3.5%) h-1. The conversion 
factor was estimated to be 382 µg/109.
Discussion
This is the first study to evaluate the bidirectional interaction 
between a nanoparticle agent and the monocytes of the MPS in 
patients using PK–PD modeling. These findings and approach 
can be applied to the more than 300 other nanoparticle 
formulations of anticancer agents that are currently in 
development. Thus, this is a very novel study with a far-
reaching impact. The evaluation of the relationship between 
liposomal drug PK and PD and the involvement of monocytes 
is of the utmost importance because the nonlinear PK of the 
liposomal drug may be explained by the saturation of MPS. 
In addition, this relationship can also explain the bidirectional 
interaction between liposomal drugs and monocytes. We 
developed a mechanism-based population PK–PD model 
that described the relationship between PEGylated liposomal 
anticancer drugs and monocyte changes in patients with 
solid tumors, using S-CKD602 as a representative of this 
class. In this model, an irreversible binding of liposomal 
drug to monocyte was used to account for the bidirectional 
interaction between PEGylated liposomal anticancer drug 
and monocyte. This model adequately described the observed 
data, as illustrated in Figure 3A, B, and Table 2.
In the mechanism-based model, the mean V
encap
 was 4.1 L 
and is close to plasma volume in humans. The estimated V
encap
 
is consistent with our prior PK study of S-CKD602, in which 
V
encap
 for patients with nonlinear clearance of encapsulated 
CKD-602 was estimated to be 2.1 ± 0.7 L/m2. In addition, 
the limited V
encap
 is consistent with other liposomal anticancer 
agents, as the size of liposomes limited their distribution to the 
normal tissue.17,36 The half-life of monocytes was estimated to 
be 102 hours, which is close to but longer than the reported 
half-life of monocytes in healthy humans (mean 72 hours, range 
36–104 hours).37,38 This discrepancy might be explained by 
the limited number of PD data, and lack of information about 
removal rate constant in the data. In this model, S-CKD602 
was eliminated via uptake by monocytes (as represented by k
a 
⋅ 
A
Encap 
⋅ Mono) and linear degradation (as represented by kdeg ⋅ 
A
Encap
). The association rate constant for uptake by monocytes 
(1.9 L
 
⋅ h-1) is much greater than the estimated kdeg (0.0178 h-1). 
This suggests the importance of the uptake of liposomal drugs 
by monocytes in blood in determining the elimination of 
S-CKD602 from the central compartment.
The conversion factor was introduced to the mechanism-
based model to bridge the unit gap between amount of 
PEGylated liposomal drug and monocyte count. In our study, 
we have the monocyte absolute count data in units of number 
of cells per liter, and the encapsulated CKD-602 amount in 
micrograms. As the liposome interacts with monocyte via the 
receptor on the cell surface and the monocyte count is not 
equal to the concentration of receptors, it is not appropriate to 
convert the monocyte count data using molar unit. Therefore, 
we needed this conversion factor to address this issue in the 
model. We performed modeling on the data with encapsulated 
CKD-602 amount in micrograms and in moles separately. 
The results from these two different data sets were similar 
(data not shown).
K
deg
 through routes other than uptake by monocytes was 
important in the mechanism-based model. We tested the 
Table 2 Population PK–PD parameters obtained from the mechanism-based model for encapsulated CKD-602 and monocytes
Parameter Definition Population mean  
RSEa (%)
IIVb, CV%c 
RSEa (%)
VEncap (L) Volume of distribution for encapsulated CKD-602 4.10 (11) 58.9 (35)
ka (L/h) Association rate constant 1.9 (47) 16.9 (75)
kdeg (1/h) Degradation rate constant of S-CKD602 0.0178 (28) 50.6 (42)
Mono0 (10
9/L) Baseline monocyte count 0.671 (7.7) 29.9 (45)
kout (1/h) Removal rate constant of monocyte 0.00677 (18) 3.5 (195)
SFactor (µg/109) Conversion factor 382 (34) 99.3 (89)
Residual variability
Proportional error (variability as %) 
 Encapsulated CKD-602 
 Monocytes
 
19.3% (45) 
10.2% (48)
 
NAd 
NAd
Additive error 
 Encapsulated CKD-602 (µg/L) 
 Monocytes (109/L)
 
9.02 (42) 
0.0471 (30)
 
NAd 
NAd
Notes: aRelative standard error for estimate; binterindividual variability; ccoefficient of variation; dnot applicable.
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model with and without k
deg
. Deletion of k
deg
 from the final 
mechanism-based model resulted in an increase in Akaike’s 
information criterion of 86. It is known that the primary 
accumulation sites of liposomes are in the liver (eg, Kupffer 
cells) and spleen.39,40 Therefore, the contribution of other 
routes is also very important to PK of S-CKD602.
In the myelosuppression-based model, the half-life 
of monocytes was estimated to be 9.0 hours, which is 
much shorter than the half-life of monocytes estimated 
from the mechanism-based model and the reported value 
from literature. This may be due to direct cytotoxicity 
of liposomes on monocytes in blood. This may also be 
explained by the different structures between these two 
models. The myelosuppression-based model incorporated 
three transit compartments, and the rate constant between 
each compartment was the same and equal to the removal 
rate constant of monocytes from blood circulation. Thus, the 
offset of the toxic effect on monocyte was counted by three 
transit compartments in the myelosuppression-based model, 
whereas, it was counted by one step in the mechanism-based 
model.
The population prediction of PK data obtained from 
the mechanism-based model had a higher correlation 
with the observed PK data, compared with that from 
myelosuppression-based model. This may suggest that 
incorporation of bidirectional interaction between PEGylated 
liposomal anticancer agents and monocytes in the model 
helped to explain the interindividual variability in the PK of 
S-CKD602. The population prediction of PK data from the 
mechanism-based model was lower than the observed PK 
data at higher concentration level. This may suggest that the 
degradation of S-CKD602 through other routes was saturated 
at high concentration levels.
Both of the mechanism-based and myelosuppression-
based PK–PD models described the observed PD data of 
monocytopenia. This suggests that both the chemotherapy-
induced myelosuppression and the bidirectional interaction 
between PEGylated liposomal anticancer agents and 
monocytes are important to describe the PD profile of 
monocytes after administration of S-CKD602. However, 
these two models predicted two different time courses of 
monocyte count change after administration of S-CKD602. 
The myelosuppression-based model predicted a day of nadir 
at around the observed day of nadir, whereas the mechanism-
based model predicted an earlier day of nadir compared with 
the observed. As no monocyte count was collected at the 
earlier time after administration of S-CKD602, the exact 
monocyte profile at earlier time points needs to be determined 
in future studies. Prior studies have reported early monocytes 
nadirs after administration of liposomal and nanoparticle 
agent. The PD profile of monocytes reached nadir at 2 days 
after administration of liposomal alendonate in rats.41 The 
half-life of monocytes in rats is about 2 days, which is 
similar to the reported half-life of monocytes in humans.37,38 
The PD profile of monocytopenia after administration of 
liposomal alendonate suggested that the day of monocyte 
nadir after administration of S-CKD602 may be earlier than 
the observed value (8.6 ± 3.3 days). Thus, cytotoxic effects 
in blood and in bone marrow may both explain the decrease 
in monocytes after administration of PEGylated liposomal 
anticancer agents.
The mechanism-based model overestimated the monocyte 
count at lower monocyte counts and underestimated the 
monocyte count at higher monocyte counts, compared with 
the myelosuppression-based model. This may be explained 
by the absence of a feedback loop in the mechanism-based 
model. We tested the myelosuppression-based model 
without the feedback loop, which produced a more serious 
overestimation of monocyte count at lower monocyte 
counts and underestimation of monocyte count at higher 
monocyte counts, than mechanism-based model (data not 
shown). No feedback mechanism has been reported for 
monocytes. The better PD fit of the myelosuppression-
based model suggests that feedback loop may be applicable 
for monocytes. However, the addition of a feedback loop 
in the development of the mechanism-based model did not 
improve the PD fits.
The purpose of this study was to develop a model 
describing and predicting PK and PD of PEGylated 
liposomal drugs in patients. Development of a PK–PD model 
relies on sufficient data from a well-designed study. In the 
Phase I PK study of S-CKD602, monocyte counts were 
collected weekly as a measure of toxicity. A better description 
of monocytopenia requires at least one observation of 
monocyte counts before a nadir. However, in this Phase I PK 
study, data were not collected between time 0 and the apparent 
time to nadir, which was 7 days. In addition, monocyte counts 
were measured on the same time schedule for each patient. 
Due to limitations in the design of the clinical trial, we were 
unable to include all of the physiological components in 
the mechanism-based and myelosuppression-based models. 
Although these two models had a similar performance in 
describing the data in our study, they function differently 
to predict the PK and PD of PEGylated liposomal drugs. 
In the mechanism-based model, there is a bidirectional 
interaction where the PK drives PD and PD affects PK. In the 
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myelosuppression-based model, PK drives PD but PD does 
not affect PK. Therefore, the mechanism-based model would 
be more appropriate than the myelosuppression-based model 
because the mechanism-based model would be able to predict 
a change in PK of PEGylated drug caused by a change in 
monocyte counts. Because monocytes play an important role 
in the clearance of PEGylated liposomes, the mechanism-
based model would be a better model to predict the PK and 
PD of this class of drugs.16
In conclusion, a mechanism-based PK–PD model was 
developed for encapsulated CKD-602 and monocyte counts 
in patients with advanced solid tumors. Comparison of this 
model and the myelosuppression-based model helped to 
explain the PK and PD of PEGylated liposomal anticancer 
agents, and the bidirectional interaction between PEGy-
lated liposomal agents and the monocytes. The developed 
mechanism-based PK–PD model may be useful in predicting 
the PK and optimize dosing of PEGylated liposomal agents 
to achieve a target exposure for each patient with malignant 
diseases. This model could also be used to describe the bidi-
rectional interaction between PK and monocytes for other 
nanoparticle and conjugated anticancer agents, as a method 
to profile and classify these agents. In the future, we will 
evaluate the bidirectional interaction between nonpegylated 
liposomal anticancer agents and monocytes, using the devel-
oped mechanism-based PK–PD model.
Acknowledgment
This work was supported by ALZA, Mountain View, CA 
and NIH/NCCR/GCRC grant 5M01 RR 00056.
Disclosure
The authors declare that there are no conflicts of interest in 
this work.
References
1. Zamboni WC, Strychor S, Joseph E, et al. Plasma, tumor, and tissue 
disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonli-
posomal CKD-602 in mice bearing A375 human melanoma xenografts. 
Clin Cancer Res. 2007;13(23):7217–7223.
2. Zamboni WC, Eiseman JL, Strychor S, et al. Tumor disposition of 
pegylated liposomal CKD-602 and the reticuloendothelial system in 
preclinical tumor models. J Liposome Res. 2011;21(1):70–80.
3. Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of 
anticancer agents. Clin Cancer Res. 2005;11(23):8230–8234.
4. Crul M. CKD-602. Chong Kun Dang. Curr Opin Investig Drugs. 2003; 
4(12):1455–1459.
5. Lee JH, Lee JM, Lim KH, et al. Preclinical and phase I clinical studies 
with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci. 2000; 
922:324–325.
6. Lee DH, Kim SW, Suh C, et al. Belotecan, new camptothecin analogue, 
is active in patients with small-cell lung cancer: results of a multicenter 
early phase II study. Ann Oncol. 2008;19(1):123–127.
 7. Yu NY, Conway C, Pena RL, Chen JY. STEALTH liposomal CKD-602, 
a topoisomerase I inhibitor, improves the therapeutic index in human 
tumor xenograft models. Anticancer Res. 2007;27(4B):2541–2545.
 8. Zamboni WC, Friedland DM, Ramalingam S, et al. Final results of a 
phase I and pharmacokinetic study of STEALTH liposomal CKD-602 
(S-CKD602) in patients with advanced solid tumors. J Clin Oncol 
(Meeting Abstracts). 2006;24(Suppl 18):S2013.
 9. Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, 
and excretion of irinotecan (CPT-11) following I.V. infusion of 
[(14)C]CPT-11 in cancer patients. Drug Metab Dispos. 2000;28(4): 
423–433.
 10. Zamboni WC, Stewart CF, Thompson J, et al. Relationship between 
topotecan systemic exposure and tumor response in human 
neuroblastoma xenografts. J Natl Cancer Inst. 1998;90(7):505–511.
 11. Stewart CF, Zamboni WC, Crom WR, et al. Topoisomerase I interactive 
drugs in children with cancer. Invest New Drugs. 1996;14(1):37–47.
 12. Zamboni WC. Concept and clinical evaluation of carrier-mediated 
anticancer agents. Oncologist. 2008;13(3):248–260.
 13. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacoge-
netic analysis of irinotecan neutropenia and pharmacokinetics. J Clin 
Oncol. 2009;27(16):2604–2614.
 14. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional 
liposomes: effect of dose. Biochim Biophys Acta. 1991;1068(2): 
133–141.
 15. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized 
liposomes: improvements in pharmacokinetics and antitumor therapeutic 
efficacy. Proc Natl Acad Sci U S A. 1991;88(24):11460–11464.
 16. Zamboni WC, Maruca LJ, Strychor S, et al. Bidirectional pharmacody-
namic interaction between pegylated liposomal CKD-602 (S-CKD602) 
and monocytes in patients with refractory solid tumors. J Liposome Res. 
2011;21(2):158–165.
 17. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. 
Science. 2004;303(5665):1818–1822.
 18. Kondo M, Oshita F, Kato Y, Yamada K, Nomura I, Noda K. Early 
monocytopenia after chemotherapy as a risk factor for neutropenia. 
Am J Clin Oncol. 1999;22(1):103–105.
 19. Oshita F, Yamada K, Nomura I, Tanaka G, Ikehara M, Noda K. 
Prophylactic administration of granulocyte colony-stimulating 
factor when monocytopenia appears lessens neutropenia caused 
by chemotherapy for lung cancer. Am J Clin Oncol. 2000;23(3): 
278–282.
 20. Friberg LE, Freijs A, Sandström M, Karlsson MO. Semiphysiological 
model for the time course of leukocytes after varying schedules 
of 5-fluorouracil in rats. J Pharmacol Exp Ther. 2000;295(2): 
734–740.
 21. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model 
of chemotherapy-induced myelosuppression with parameter consistency 
across drugs. J Clin Oncol. 2002;20(24):4713–4721.
 22. Minami H, Sasaki Y, Saijo N, et al. Indirect-response model for the 
time course of leukopenia with anticancer drugs. Clin Pharmacol Ther. 
1998;64(5):511–521.
 23. Krzyzanski W, Jusko WJ. Multiple-pool cell lifespan model of hema-
tologic effects of anticancer agents. J Pharmacokinet Pharmacodyn. 
2002;29(4):311–337.
 24. Woo S, Krzyzanski W, Jusko WJ. Pharmacodynamic model for 
chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol. 
2008;62(1):123–133.
 25. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population 
pharmacokinetic-pharmacodynamic model for neutropenia with patient 
subgroup identification: comparison across anticancer drugs. Clin 
Cancer Res. 2006;12(18):5481–5490.
 26. Léger F, Loos WJ, Bugat R, et al. Mechanism-based models for topotecan-
induced neutropenia. Clin Pharmacol Ther. 2004;76(6):567–578.
 27. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD. 
A semimechanistic-physiologic population pharmacokinetic/
pharmacodynamic model for neutropenia following pemetrexed 
therapy. Cancer Chemother Pharmacol. 2006;57(4):412–426.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5563
Mechanism-based model of S-CKD602 and monocytes
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2012:7
 28. Fetterly GJ, Grasela TH, Sherman JW, et al. Pharmacokinetic/
pharmacodynamic modeling and simulation of neutropenia during 
phase I development of liposome-entrapped paclitaxel. Clin Cancer 
Res. 2008;14(18):5856–5863.
 29. van Kesteren C, Zandvliet AS, Karlsson MO, et al. Semi-physiological 
model describing the hematological toxicity of the anti-cancer agent 
indisulam. Invest New Drugs. 2005;23(3):225–234.
 30. Zamboni WC, Ramalingam S, Friedland DM, et al. Phase I and 
pharmacokinetic study of pegylated liposomal CKD-602 in patients with 
advanced malignancies. Clin Cancer Res. 2009;15(4):1466–1472.
 31. Zamboni WC, Strychor S, Maruca L, et al. Pharmacokinetic study of 
pegylated liposomal CKD-602 (S-CKD602) in patients with advanced 
malignancies. Clin Pharmacol Ther. 2009;86(5):519–526.
 32. McKenzie SB. Clinical Laboratory Hematology. 2nd ed. Upper Saddle 
River, NJ: Prentice Hall; 2010.
 33. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. 
1st ed. New York, NY: Springer Science and Business Media, Inc; 2005.
 34. Sheiner LB, Beal SL. Evaluation of methods for estimating population 
pharmacokinetics parameters. I. Michaelis-Menten model: routine 
clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8(6): 
553–571.
 35. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population char-
acteristics of pharmacokinetic parameters from routine clinical data. 
J Pharmacokinet Biopharm. 1977;5(5):445–479.
 36. Hilger RA, Richly H, Grubert M, et al. Pharmacokinetics (PK) of 
a liposomal encapsulated fraction containing doxorubicin and of 
doxorubicin released from the liposomal capsule after intravenous 
infusion of Caelyx/Doxil. Int J Clin Pharmacol Ther. 2005;43(12): 
588–589.
 37. Jain NC. Essentials of Veterinary Hematology. 1st ed. Hoboken, NJ: 
John Wiley and Sons; 1993.
 38. Whitelaw DM. Observations on human monocyte kinetics after pulse 
labeling. Cell Tissue Kinet. 1972;5(4):311–317.
 39. Koning GA, Morselt HW, Kamps JA, Scherphof GL. Uptake and intra-
cellular processing of PEG-liposomes and PEG-immunoliposomes by 
kupffer cells in vitro 1*. J Liposome Res. 2001;11(2–3):195–209.
 40. Van Rooijen N, Sanders A. Kupffer cell depletion by liposome-delivered 
drugs: comparative activity of intracellular clodronate, propamidine, and 
ethylenediaminetetraacetic acid. Hepatology. 1996;23(5):1239–1243.
 41. Haber E, Afergan E, Epstein H, et al. Route of administration-dependent 
anti-inflammatory effect of liposomal alendronate. J Control Release. 
2010;148(2):226–233.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
5564
Wu et al
